Clinical Trial

A Phase Ib Study of RC1416 Injection

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-28; most recent amendment 2026-01-29.
Status change: Recruiting → Completed 2026-01-29
Status change: Not Yet Recruiting → Recruiting 2025-07-02
Trial Details
NCT Number NCT06911866
Lead Sponsor Nanjing RegeneCore Biotech Co., Ltd.
Conditions Moderate to Severe Asthma
Enrollment 40 participants
Start Date 2024-10-25
Primary Completion 2025-09-25 (estimated)
Study Completion 2025-09-25 (estimated)
Updated on ClinicalTrials.gov 2026-01-30